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Obesity is now recognised as a major global health problem. It accounts for a large proportion of the 
population and is increasing in both developed and developing countries. Epidemiological evidence and 
studies in animal models showed that obesity increased the incidence of colon cancer. As obesity is 
difficult to prevent and treat, it is important to find effective approaches to prevent obesity-associated 
colon cancer. The prevention strategy should be different from that used for the treatment as clinically 
used drugs are not suitable for the prevention due to side-effects and cost. Phytochemicals are ideal for 
the prevention. This review summarises the effect of green tea component (-)-epigallocatechin-3 gallate 
and turmeric component curcumin in the prevention of obesity-associated colon cancer and the 
mechanisms for their preventive effects. Both agents have been demonstrated to reduce obesity 
increased polyp formation in animal models and inhibit PI3K/Akt and MAPK signal pathways. 
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Introduction
Obesity is now recognised as a major global health problem. 
It accounts for a large proportion of the population and 
is increasing in both developed and developing countries. 
Obesity can cause many co-morbidities including cancer, 
heart disease, osteoarthritis and diabetes (1-8). Among 
them, obesity-associated colon cancer has been studied 
extensively. Several epidemiological studies showed that 
obesity increased the incidence of colon cancer (9,10). This 
is further demonstrated in animal models. Two common 
animal models have been employed in colon cancer study: 
genetic defect model - Apcmin/- and chemical azoxymethane 
(AOM)-induced colon polyp model (11,12). Obesity has 
been demonstrated to increase colon polyp formation in 
both models (13,14).
As it is difficult to prevent or treat obesity at present, 
prevention of obesity-associated colon is an important issue. 
To be able to prevent obesity-associated colon cancer, it 
would be great helpful to understand the mechanisms of 
the disease. Indeed, the mechanisms for obesity-associated 
colon cancer are now partially elucidated. It is known that 
multiple cancer risk factors that are increased in obesity are 
responsible for increased incidence of colon cancer cancer 
(1,15,16). The main increased risk factors include elevated 
levels of insulin, insulin-like growth factor-1 (IGF-1), leptin, 
interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-alpha 
and decreased levels of adiponection (14,17-24). These 
factors in turn cause activation of multiple signal pathways 
which play key roles in obesity-associated colon cancer 
such as, phosphoinositide 3-kinase/protein kinase B (PI3K/
Akt), mitogen activated protein kinase (MAPK) and signal 
transducer and activator of transcription 3 (STAT3) (25,26). 
Thus, inhibition of these factors and associated pathways 
can be used to prevent or treat obesity-associated colon 
cancer (27,28). Although many approaches can be used to 
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inhibit these pathways, phytochemicals may be the best to be 
used for the prevention due to low side-effects and low cost. 
This review focuses on the effects of green tea component 
(-)-epigallocatechin-3 gallate (EGCG) and turmeric 
component curcumin in the prevention of obesity-associated 
colon cancer and the mechanisms for such effects.
Signalling pathways in the initiation of obesity-
associated colon cancer and prevention 
implications
Several studies showed that the PI3K/Akt pathway play a key 
role in obesity-associated colon cancer (25). A most recent 
study demonstrated the importance of the PI3K/Akt and 
MAPK in the initiation of obesity -associated colon cancer 
in A/J mice (29). High-fat diet was shown to increase AOM-
induced colon carcinogenesis. In these mice, the activity of the 
PI3K/Akt pathway is increased as detected by phosphorylated 
Akt. Activation of MAPK pathway is indicated by p-ErK1/2. In 
addition, anti-apoptotic protein bcl-xl and cell cycle regulator 
cyclin D1 are increased. This study thus demonstrated that 
both pathways are important in the initiation of obesity-
associated colon cancer and provide the basis for the 
prevention of obesity-associated colon cancer.
Various approaches have been used to inhibit these 
signalling pathways to prevent obesity-associated cancer. 
In energy restrict model, it has been shown that 30% 
decrease in energy could decrease AOM-induced polyp 
numbers markedly (30). Calorie restrict reduced IGF-1 and 
associated signal pathways (31). An angiotensin-converting 
enzyme (ACE) inhibitor captopril and angiotensin-II type 1 
receptor blocker (ARB) telmisartan can also decrease AOM-
induced colon cancer in obese mouse model (32). Pitvastatin 
and branch amino acids are effective in the prevention of 
colon cancer in db/db obese model (33,34). However, clinic 
drugs may be not practical to be used for the prevestion of 
obesity-associated colon cancer as they are expensive and 
have side-effects. Alternatively, phytochemicals may be ideal 
for prevention.
Effects of phytochemicals on obesity-associated 
colon cancer
Phytochemicals have been studied extensively for 
the prevention of cancer. It has been estimated that 
phytochemicals can reduce cancer risk as much as 20% 
via inhibition of cell cycle and increase of apoptosis as 
well as increase of host immune responses (35). Several 
phytochemicals have been shown to be effective on the 
prevention of obesity-associated colon cancer. Eskin et al. 
demonstrated that mustard mucilage was shown to inhibit 
obesity-associated colon cancer (36). A meta-analysis 
showed that coffee consumption decreased the incidence 
of colon cancer (37,38). Flavonoids (chrysin, quercetin and 
nobiletin) is also effective in AOM/db/db model (39). The 
effects of EGCG and curcumin are decribed in details in 
below sections.
EGCG
Green tea, made from the leaves of the plant Camellia 
sinensis, is a common beverage in China for thousands of 
years and now is popular worldwide. Many health beneficial 
properties of green tea have been revealed such as anti-
inflammatry, anti-hypertensive, hypocholesterolemic, 
hypoglycemic, antidiabetic and anti-carcinogenic effects 
(40-43). The components of green tea include polyphenolic 
compounds (catechins): EGCG, (-)-epigallocatechin (EGC), 
(-)-epicatechin-3-gallate (ECG) and (-)-epicatechin (EC), 
and flavonols: quercetin, kaempferol and myricitin (44). 
EGCG is a main component of green tea and has been 
studied extensively in the prevention of cancer (45).
The preventive effect of green tea and EGCG in colon 
cancer carcinogenesis has been demonstrated in both 
Apcmin/- and AOM animal models. Green tea extract alone 
or in combination with sulindac reduced intestinal tumour 
formation via down-regulation of beta-catenin in Apcmin/- 
mouse model (12,46). Ju et al. showed that EGCG can 
effectively prevent colon cancer carcinogenesis in this 
model (47). EGCG was also demonstrated to reduce polyp 
formation in AOM model of colon cancer (48,49).
Several studies have extended the study of EGCG to 
prevent obesity-associated colon cancer. Shimiz et al. showed 
that EGCG at concentrations 0.01% or 0.1% in drinking 
water significantly decreased the number of total aberrant 
crypt foci induced by AOM in obese C57BL/KsJ-db/db mice, 
via reduction of beta-catenin (50). High-fat diet feeding is 
a common model for obesity-associated cancer which has 
been shown to increase colon cancer incidence. Ju et al. 
showed that 0.6% of EGCG in drinking water reduced 
AOM-induced abbarrant crypt foci formation in high-fat 
diet induced obese mice (51).
The mechanisms for the preventive effect of EGCG on 
carcinogenesis have been elucidated to be its properties 
to inhibit multiple signal pathways (52). EGCG can inhibit 
both PI3K/Akt and MAPK pathways (47) (Figure 1), which 
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are important in obesity-associated colon cancer. EGCG also 
interacts directly with the PI3K downsteam target bcl-2, an 
anti-apoptotic protein (53,54). EGCG can inhibit NF-
κB, a transcriptional factor, also a downstream target of 
the PI3K/Akt pathway (55). Therefore, EGCG can cause 
cell cycle arrest (56). The effects of EGCG on cancer risk 
factors increased in obesity include increasing serum level 
of IGFBP-3, decreasing the serum levels of IGF-I, insulin 
and leptin. Therefore, EGCG can inhibit activated signal 
pathways of obesity-associated colon cancer at multiple 
points (50).
Curcumin
Tumeric, derived from the plant Curcuma longa L of the 
Zingiberaceae family, has been used as a medicinal agent for 
thousands of years in Asian countries (57,58). Curcumin is 
a major component of the spice turmeric which has similar 
chemical structure of aspirin, a well known chemical that 
can prevent carcinogenesis (59).
In vitro studies, curcumin has been shown to decrease 
proliferation and increase apoptosis in several colon cancer cell 
lines. Addition of curcumin at the concentration of 50 µM to 
cultured colon cancer cell line HT29 induced apoptosis (60-62). 
Curcumin was also shown to effectively inhibit the growth 
of HCT116 cells that survived through fluorouracil and 
oxaliplatin treatment (63,64). Wei et al. tested the effect of 
curcumin on 5 cell lines SW480, HCT116, LoVo, SW48, 
HCT15 and demonstrated it caused apoptosis in all these 
cells (65). The preventive effect of curcumin on colon cancer 
has been confirmed in animal models of colon cancer (66).
It has been demonstrated that curcumin can inhibit tumour 
initiation in obese animal models. Pettan-Brewer et al. showed 
that diet containing 35% of fat increase polyp number by 
23% and 0.5% curcumin reversed the high-fat accelerated 
polyp formation in an Apcmin/- mouse model (67). Curcumin 
increased apoptosis and DNA repair. It also reduced 
high-fat induced weight gain in the model. The anti-
obesity property of curcumin (57,68) could also mediate its 
preventive effect on obesity-associated colon cancer. Kubota 
investigated the effect of curcumin in C57BL/KsJ-db/db 
obese mice in AOM model and found that 0.2% and 2% 
curcumin feeding reduced polyp formation markedly (69-71).
The  mechan i sms  for  the  pro tec t i ve  e f f ec t  o f 
curcumin on carcinogensis in obesity-associated colon 
cancer are multiple. Curcumin can inhibit MAPK and 
Akt pathways (63) (Figure 2). It has been shown to reduce 
TNF-alpha-induced NF-κB. Curcumin reduced levels of 
TNF-alpha, IL-6, IGF-1 receptor and cyclooxygenase-2 
(COX2) mRNA (63). Cox-2 was considered to be a good 
target for the prevention of colon cancer (72). Indeed, 
increased Cox-2 is also involved in obesity-associated 
colon cancer (73).  In addition, curcumin reduces 
inflammation in obesity (74).
Curcumin is not well dissolved in water and this limits its 
bioavailability. Nanotechnology has been used to increase 
its bioavailability and a polymeric nanocarrier-curcumin 
(PNCC) has been used for colon cancer prevention in 
AOM-induced tumours in rats (75). PNCC markedly 
reduced tumour number and size with decreased cell 
proliferation and increased apoptosis. The study showed 
that beta-catennin and Bcl-2 proteins were decreased and 


















Figure 1 The effect of EGCG on signal pathways in obesity-
associated colon cancer. EGCG inhibits multiple components 
of cancer risk factors and associated signal pathways inobesity-
associated colon cancer. It reduces leptin and insulin/IGF-1 levels 
and inhibits PI3K/Akt, MAPK, bcl-2 and NF-κB. Abbreviation: 
EGCG, (-)-epigallocatechin-3 gallate; IL6, interleukin 6; IGF-1, 
insulin-like growth factor-1; PI3K/Akt, phosphoinositide 3-kinase/
protein kinase B; MAPK, mitogen activated protein kinase; bcl-2, 
B-cell lymphoma 2; NF-κB, nuclear factor-kappaB
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also been developed to increase its effectiveness (76-79).
Combinatorial implications of EGCG and 
curcumin
As both EGCG and curcumin have preventive effects 
on obesity-associated colon cancer, it is interesting to 
investigate whether combination of both agents has 
synergistic effect. Indeed, two studies have revealed the 
synergistic effect of EGCG and curcumin. Manikandan 
showed that EGCG and curcumin produced highest 
levels of inhibitory effect on HCT15 and HCT116 cells 
in combination although EGCG and curcumin can cause 
apoptosis individually (38). Kondo et al. also showed that 
EGCG significantly lowed the dose needed for curcumin 
to inhibit pAkt/mTOR pathway (80). Further studies are 
needed to characterise the effect of combinatorial use of 
EGCG and curcumin on obesity-associated colon cancer 
and on the key signalling molecules.
Conclusions
Both EGCG and curcumin have been demonstrated to 
have preventive effects on obesity-associated colon cancer. 
The mechanisms are their properties to inhibit multiple 
signalling pathway components especially that in PI3K/
Akt and MAPK pathways. These components are activated 
in obesity and responsible for increased incidence of 
colon cancer. Combinational use of EGCG and curcumin 
produced synergistic effect on colon cancer cells. Further 
studies are warrant for such as effect in the obesity-
associated colon cancer model and to characterise the 
inhibition of signalling molecules.
Acknowledgements
Disclosure: The author declares no conflict of interest.
References
1. Drew JE. Molecular mechanisms linking adipokines to 
obesity-related colon cancer: focus on leptin. Proc Nutr 
Soc 2012;71:175-80.
2. Percik R, Stumvoll M. Obesity and cancer. Exp Clin 
Endocrinol Diabetes 2009;117:563-6.
3. Wolin KY, Carson K, Colditz GA. Obesity and cancer. 
Oncologist 2010;15:556-65.
4. Ning Y, Wang L, Giovannucci EL. A quantitative analysis 
of body mass index and colorectal cancer: findings from 56 
observational studies. Obes Rev 2010;11:19-30.
5. Vance V, Mourtzakis M, McCargar L, et al. Weight gain 
in breast cancer survivors: prevalence, pattern and health 
consequences. Obes Rev 2011;12:282-94.
6. Ali AS, Ali S, Ahmad A, et al. Expression of microRNAs: 
potential molecular link between obesity, diabetes and 
cancer. Obes Rev 2011;12:1050-62.
7. Gill RS, Al-Adra DP, Shi X, et al. The benefits of bariatric 
surgery in obese patients with hip and knee osteoarthritis: 
a systematic review. Obes Rev 2011;12:1083-9.
8. Runhaar J, Koes BW, Clockaerts S, et al. A systematic 
review on changed biomechanics of lower extremities 
in obese individuals: a possible role in development of 
osteoarthritis. Obes Rev 2011;12:1071-82.
9. Ben Q, An W, Jiang Y, et al. Body mass index increases 
Figure 2 The effect of curcumin on signal pathways in obesity-
associated colon cancer. The figure shows that curcumin 
reduces IL-6, TNF-alpha leptin and insulin/IGF-1 levels and 
inhibits PI3K/Akt, MAPK and NF-κB. Abbreviation: EGCG, 
(-)-epigallocatechin-3 gallate; IL6, interleukin 6; IGF-1, insulin-
like growth factor-1; PI3K/Akt, phosphoinositide 3-kinase/protein 
kinase B; MAPK, mitogen activated protein kinase; bcl-2, B-cell 

















247Translational Gastrointestinal Cancer, Vol 1, No 3 October 2012
© AME Publishing Company. All rights reserved. Transl Gastrointest Cancer 2012;1(3):243-249www.amepc.org/tgc
risk for colorectal adenomas based on meta-analysis. 
Gastroenterology 2012;142:762-72.
10. Pischon T, Lahmann PH, Boeing H, et al. Body size and 
risk of colon and rectal cancer in the European Prospective 
Investigation Into Cancer and Nutrition (EPIC). Natl 
Cancer Inst 2006;98:920-31.
11. Chen J, Huang XF. The signal pathways in azoxymethane-
induced colon cancer and preventive implications. Cancer 
Biol Ther 2009;8:1313-7.
12. Orner GA, Dashwood WM, Blum CA, et al. Suppression 
of tumorigenesis in the Apc(min) mouse: down-regulation 
of beta-catenin signaling by a combination of tea plus 
sulindac. Carcinogenesis 2003;24:263-7.
13. Teraoka N, Mutoh M, Takasu S, et al. High susceptibility 
to azoxymethane-induced colorectal carcinogenesis in 
obese KK-Ay mice. Int J Cancer 2011;129:528-35.
14. Flores MB, Rocha GZ, Damas-Souza DM, et al. Obesity-
Induced Increase in Tumor Necrosis Factor-α Leads to 
Development of Colon Cancer in Mice. Gastroenterology 
2012;143:741-53.e4.
15. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway 
and colon cancer. Obes Rev 2009;10:610-6.
16. Sikalidis AK, Varamini B. Roles of hormones and signaling 
molecules in describing the relationship between obesity 
and colon cancer. Pathol Oncol Res 2011;17:785-90.
17. Gislette T, Chen J. The possible role of IL-17 in obesity-
associated cancer. Scientific World Journal 2010;10:2265-71.
18. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like 
growth factor (IGF)-I, IGF binding protein-3, and cancer 
risk: systematic review and meta-regression analysis. 
Lancet 2004;363:1346-53.
19. Chen J, Katsifis A, Hu C, et al. Insulin decreases 
therapeutic efficacy in colon cancer cell line HT29 via the 
activation of the PI3K/Akt pathway. Curr Drug Discov 
Technol 2011;8:119-25.
20. Paz-Filho G, Lim EL, Wong ML, et al. Associations 
between adipokines and obesity-related cancer. Front 
Biosci 2011;16:1634-50.
21. Renehan AG, Dive C. Obesity, insulin and chemoresistance 
in colon cancer. J Gastrointest Oncol 2011;2:8-10.
22. Chen J, Huang XF, Qiao L, et al. Insulin caused drug 
resistance to oxaliplatin in colon cancer cell line HT29. J 
Gastrointest Oncol 2011;2:27-33.
23. Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-
intestinal malignancies. Obes Rev 2010;11:863-74.
24. Johnson C, Han Y, Hughart N, et al. Interleukin-6 and its 
receptor, key players in hepatobiliary inflammation and 
cancer. Transl Gastrointest Cancer 2012;1:58-70.
25. Chen J. Multiple signal pathways in obesity-associated 
cancer. Obes Rev 2011;12:1063-70.
26. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway 
and colon cancer. Obes Rev 2009;10:610-6.
27. Chen JZ. Targeted therapy of obesity-associated colon 
cancer. Transl Gastrointest Cancer 2012;1:44-57.
28. Chen J, Wang B. The roles of miRNA-143 in colon cancer 
and therapeutic implications. Transl Gastrointest Cancer 
2012;1:169-74.
29. Park SY, Kim JS, Seo YR, et al. Effects of diet-induced 
obesity on colitis-associated colon tumor formation in A/J 
mice. Int J Obes (Lond) 2012;36:273-80.
30. Moore T, Beltran L, Carbajal S, et al. Dietary energy 
balance modulates signaling through the Akt/mammalian 
target of rapamycin pathways in multiple epithelial tissues. 
Cancer Prev Res (Phila) 2008;1:65-76.
31. Harvey AE, Lashinger LM, Otto G, et al. Decreased 
systemic IGF-1 in response to calorie restriction modulates 
murine tumor cell growth, nuclear factor-κB activation, 
and inflammation-related gene expression. Mol Carcinog 
2012. [Epub ahead of print].
32. Kubota M, Shimizu M, Sakai H, et al. Renin-angiotensin 
system inhibitors suppress azoxymethane-induced colonic 
preneoplastic lesions in C57BL/KsJ-db/db obese mice. 
Biochem Biophys Res Commun 2011;410:108-13.
33. Yasuda Y, Shimizu M, Shirakami Y, et al. Pitavastatin 
inhibits azoxymethane-induced colonic preneoplastic 
lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 
2010;101:1701-7.
34. Shimizu M, Shirakami Y, Iwasa J, et al. Supplementation 
with branched-chain amino acids inhibits azoxymethane-
induced colonic preneoplastic lesions in male C57BL/KsJ-
db/db mice. Clin Cancer Res 2009;15:3068-75.
35. Bradford PG, Awad AB. Phytosterols as anticancer 
compounds. Mol Nutr Food Res 2007;51:161-70.
36. Eskin NA, Raju J, Bird RP. Novel mucilage fraction of 
Sinapis alba L. (mustard) reduces azoxymethane-induced 
colonic aberrant crypt foci formation in F344 and Zucker 
obese rats. Phytomedicine 2007;14:479-85.
37. Je Y, Liu W, Giovannucci E. Coffee consumption and 
risk of colorectal cancer: a systematic review and meta-
analysis of prospective cohort studies. Int J Cancer 
2009;124:1662-8.
38. Manikandan R, Beulaja M, Arulvasu C, et al. Synergistic 
anticancer activity of curcumin and catechin: an in vitro 
study using human cancer cell lines. Microsc Res Tech 
2012;75:112-6.
39. Miyamoto S, Yasui Y, Ohigashi H, et al. Dietary flavonoids 
248 Chen. Prevent obesity-associated colon cancer by EGCG and curcumin
© AME Publishing Company. All rights reserved. Transl Gastrointest Cancer 2012;1(3):243-249www.amepc.org/tgc
suppress azoxymethane-induced colonic preneoplastic 
lesions in male C57BL/KsJ-db/db mice. Chem Biol 
Interact 2010;183:276-83.
40. Benelli R, Venè R, Bisacchi D, et al. Anti-invasive effects of 
green tea polyphenol epigallocatechin-3-gallate (EGCG), 
a natural inhibitor of metallo and serine proteases. Biol 
Chem 2002;383:101-5.
41. Butt MS, Sultan MT. Green tea: nature’s defense against 
malignancies. Crit Rev Food Sci Nutr 2009;49:463-73.
42. Henning SM, Wang P, Heber D. Chemopreventive effects 
of tea in prostate cancer: green tea versus black tea. Mol 
Nutr Food Res 2011;55:905-20.
43. Singh BN, Shankar S, Srivastava RK. Green tea catechin, 
epigallocatechin-3-gallate (EGCG): mechanisms, 
perspectives and clinical applications. Biochem Pharmacol 
2011;82:1807-21.
44. Yang CS, Lambert JD, Ju J, et al. Tea and cancer 
prevention: molecular mechanisms and human relevance. 
Toxicol Appl Pharmacol 2007;224:265-73.
45. Jankun J, Selman SH, Swiercz R, et al. Why drinking 
green tea could prevent cancer. Nature 1997;387:561.
46. Suganuma M, Ohkura Y, Okabe S, et al. Combination 
cancer chemoprevention with green tea extract and 
sulindac shown in intestinal tumor formation in Min mice. 
J Cancer Res Clin Oncol 2001;127:69-72.
47. Ju J, Hong J, Zhou JN, et al. Inhibition of intestinal 
tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-
3-gallate, the major catechin in green tea. Cancer Res 
2005;65:10623-31.
48. Ohishi T, Kishimoto Y, Miura N, et al. Synergistic effects 
of (-)-epigallocatechin gallate with sulindac against colon 
carcinogenesis of rats treated with azoxymethane. Cancer 
Lett 2002;177:49-56.
49. Shirakami Y, Shimizu M, Tsurumi H, et al. EGCG and 
Polyphenon E attenuate inflammation-related mouse 
colon carcinogenesis induced by AOM plus DDS. Mol 
Med Report 2008;1:355-61.
50. Shimizu M, Shirakami Y, Sakai H, et al. 
(-)-Epigallocatechin gallate suppresses azoxymethane-
induced colonic premalignant lesions in male C57BL/KsJ-
db/db mice. Cancer Prev Res (Phila) 2008;1:298-304.
51. Ju J, Liu Y, Hong J, et al. Effects of green tea and high-
fat diet on arachidonic acid metabolism and aberrant 
crypt foci formation in an azoxymethane-induced colon 
carcinogenesis mouse model. Nutr Cancer 2003;46:172-8.
52. Yang CS, Wang H. Mechanistic issues concerning 
cancer prevention by tea catechins. Mol Nutr Food Res 
2011;55:819-31.
53. Leone M, Zhai D, Sareth S, et al. Cancer prevention 
by tea polyphenols is linked to their direct inhibition 
of antiapoptotic Bcl-2-family proteins. Cancer Res 
2003;63:8118-21.
54. Ermakova S, Choi BY, Choi HS, et al. The intermediate 
filament protein vimentin is a new target for 
epigallocatechin gallate. J Biol Chem 2005;280:16882-90.
55. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol 
epigallocatechin-3-gallate differentially modulates nuclear 
factor kappaB in cancer cells versus normal cells. Arch 
Biochem Biophys 2000;376:338-46.
56. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation 
by green tea polyphenol epigallocatechin-3-gallate. 
Biochem Biophys Res Commun 2000;275:328-34.
57. Aggarwal BB. Targeting inflammation-induced obesity and 
metabolic diseases by curcumin and other nutraceuticals. 
Annu Rev Nutr 2010;30:173-99.
58. Aggarwal BB, Harikumar KB. Potential therapeutic 
effects of curcumin, the anti-inflammatory agent, against 
neurodegenerative, cardiovascular, pulmonary, metabolic, 
autoimmune and neoplastic diseases. Int J Biochem Cell 
Biol 2009;41:40-59.
59. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in 
cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
60. Lee YK, Park SY, Kim YM, et al. Regulatory effect of the 
AMPK-COX-2 signaling pathway in curcumin-induced 
apoptosis in HT-29 colon cancer cells. Ann N Y Acad Sci 
2009;1171:489-94.
61. Goel A, Boland CR, Chauhan DP. Specific inhibition 
of cyclooxygenase-2 (COX-2) expression by dietary 
curcumin in HT-29 human colon cancer cells. Cancer Lett 
2001;172:111-8.
62. Singh N, Shrivastav A, Sharma RK. Curcumin induces 
caspase and calpain-dependent apoptosis in HT29 human 
colon cancer cells. Mol Med Report 2009;2:627-31.
63. Patel BB, Gupta D, Elliott AA, et al. Curcumin targets 
FOLFOX-surviving colon cancer cells via inhibition of 
EGFRs and IGF-1R. Anticancer Res 2010;30:319-25.
64. Watson JL, Hill R, Yaffe PB, et al. Curcumin causes 
superoxide anion production and p53-independent 
apoptosis in human colon cancer cells. Cancer Lett 
2010;297:1-8.
65. Wei SC, Lin YS, Tsao PN, et al. Comparison of the 
anti-proliferation and apoptosis-induction activities 
of sulindac, celecoxib, curcumin, and nifedipine in 
mismatch repair-deficient cell lines. J Formos Med Assoc 
2004;103:599-606.
66. Villegas I, Sánchez-Fidalgo S, de la Lastra CA. 
249Translational Gastrointestinal Cancer, Vol 1, No 3 October 2012
© AME Publishing Company. All rights reserved. Transl Gastrointest Cancer 2012;1(3):243-249www.amepc.org/tgc
Chemopreventive effect of dietary curcumin on 
inflammation-induced colorectal carcinogenesis in mice. 
Mol Nutr Food Res 2011;55:259-67.
67. Pettan-Brewer C, Morton J, Mangalindan R, et al. 
Curcumin suppresses intestinal polyps in APC Min mice 
fed a high fat diet. Pathobiol Aging Age Relat Dis 2011;1.
68. Ejaz A, Wu D, Kwan P, et al. Curcumin inhibits 
adipogenesis in 3T3-L1 adipocytes and angiogenesis and 
obesity in C57/BL mice. J Nutr 2009;139:919-25.
69. Kubota M, Shimizu M, Sakai H, et al. Preventive effects of 
curcumin on the development of azoxymethane-induced 
colonic preneoplastic lesions in male C57BL/KsJ-db/db 
obese mice. Nutr Cancer 2012;64:72-9.
70. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive 
effect of curcumin, a naturally occurring anti-inflammatory 
agent, during the promotion/progression stages of colon 
cancer. Cancer Res 1999;59:597-601.
71. Kwon Y, Magnuson BA. Effect of azoxymethane and 
curcumin on transcriptional levels of cyclooxygenase-1 
and -2 during initiation of colon carcinogenesis. Scand J 
Gastroenterol 2007;42:72-80.
72. Gupta RA, Dubois RN. Colorectal cancer prevention and 
treatment by inhibition of cyclooxygenase-2. Nat Rev 
Cancer 2001;1:11-21.
73. Delage B, Rullier A, Capdepont M, et al. The effect of 
body weight on altered expression of nuclear receptors 
and cyclooxygenase-2 in human colorectal cancers. Nutr J 
2007;6:20.
74. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin 
significantly improves obesity-associated inflammation 
and diabetes in mouse models of diabesity. Endocrinology 
2008;149:3549-58.
75. Alizadeh AM, Khaniki M, Azizian S, et al. 
Chemoprevention of azoxymethane-initiated colon cancer 
in rat by using a novel polymeric nanocarrier-curcumin. 
Eur J Pharmacol 2012;689:226-32.
76. Chen C, Liu Y, Chen Y, et al. C086, a novel analog of 
curcumin, induces growth inhibition and down-regulation 
of NFκB in colon cancer cells and xenograft tumors. 
Cancer Biol Ther 2011;12:797-807.
77. Kanwar SS, Yu Y, Nautiyal J, et al. Difluorinated-curcumin 
(CDF): a novel curcumin analog is a potent inhibitor of 
colon cancer stem-like cells. Pharm Res 2011;28:827-38.
78. Lai CS, Wu JC, Yu SF, et al. Tetrahydrocurcumin is more 
effective than curcumin in preventing azoxymethane-
induced colon carcinogenesis. Mol Nutr Food Res 
2011;55:1819-28.
79. Lin L, Liu Y, Li H, et al. Targeting colon cancer stem cells 
using a new curcumin analogue, GO-Y030. Br J Cancer 
2011;105:212-20.
80. Kondo A, Takeda T, Li B, et al. Epigallocatechin-3-
gallate potentiates curcumin›s ability to suppress uterine 
leiomyosarcoma cell growth and induce apoptosis. Int J 
Clin Oncol 2012. [Epub ahead of print].
Cite this article as: Chen J. Prevention of obesity-associated 
colon cancer by (-)-epigallocatechin-3 gallate and curcumin. 
Transl Gastrointest Cancer 2012;1(3):243-249. DOI: 10.3978/
j.issn.2224-4778.2012.09.04
